RG+A has recently implemented some key staffing changes to support the company’s ongoing growth in its biopharma forecasting and device/diagnostics lines of business.
According to members of RG+A’s Health Payer Council® (HPC®), an online community of managed care pharmacy and medical directors, biosimilar products are likely to continue to face the same scrutiny and pricing pressure from payers as their innovator counterparts, as well as competition from other biosimilar products.
RG+A Continues its Long-Standing Commitment to the Trenton Area Soup Kitchen and Says Farewell to an Exemplary Leader
Company staff volunteer time, supplies and money to “feed the need” continuing a tradition of honoring Marty Green, the father of RG+A’s President and CEO.
RG+A’s new Dynamic Practice Simulation® Line of Therapy overcomes challenges in forecasting treatment decisions for current and emerging options within highly complex diseases.
Company staff volunteer time, supplies and money to local cause in honor of Marty Green, the father of RG+A President and CEO.
RG+A Expands Leadership Team with Appointment of New Executive Vice President and Chief Operating Officer
RG+A positioned for next phase of growth with the selection of industry leader Kevin M. Kelly as the company’s Executive Vice President and Chief Operating Officer.
New Hope, PA — September 9, 2014 — Roger Green + Associates, a leading healthcare marketing research firm announced that from today on, it will be known as RG+A. The streamlined moniker reflects an enhanced focus on meeting clients’ research and insight development needs in an increasingly complex and challenging world. As the firm’s new […]